Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT) : Real-world data from Germany, presented by d-uo
Thieme. All rights reserved..
INTRODUCTION: Patients with prostate cancer often present with reduced bone mineral density. We herein present real-world data (RWD) regarding osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) receiving androgen deprivation therapy (ADT) treated by German urologists in private practice.
MATERIAL AND METHODS: This is a questionnaire-based study including members of d-uo ("Deutsche Uro-Onkologen", German uro-oncologists). Patients with nmHSPC between July 2019 and June 2020 were included. They were asked about start, type and duration of osteoprotection as well as supplementation with calcium and vitamin D.
RESULTS: Between July 2019 and June 2020, a total of 3,692 patients with prostate cancer were seen at least once in one of the private practices of 15 urologists (all d-uo members). There were 844 patients (22.9%) with nmHSPC treated with ADT. Osteoprotection using denosumab or a bisphosphonate to prevent skeletal-related events (SRE) was applied in 183/844 patients (21.7%) with nmHSPC. In patients receiving osteoprotection, denosumab was chosen in 73.2% of patients and a bisphosphonate was chosen in 26.8% of patients. Supplementation with calcium and vitamin D was given in 84.7% of patients.
CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Aktuelle Urologie - 53(2022), 6 vom: 24. Dez., Seite 517-525 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Osteoprotektion beim nichtmetastasierten hormonsensitiven Prostatakarzinom (nmHSPC) unter androgendeprivativer Therapie (ADT): Aktuelle Daten aus Deutschland, vorgelegt von d-uo |
|---|
| Beteiligte Personen: |
Klier, Jörg [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 28.11.2022 Date Revised 10.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1954-6826 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349366799 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349366799 | ||
| 003 | DE-627 | ||
| 005 | 20231226042446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-1954-6826 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349366799 | ||
| 035 | |a (NLM)36423612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Klier, Jörg |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT) |b Real-world data from Germany, presented by d-uo |
| 246 | 3 | 3 | |a Osteoprotektion beim nichtmetastasierten hormonsensitiven Prostatakarzinom (nmHSPC) unter androgendeprivativer Therapie (ADT): Aktuelle Daten aus Deutschland, vorgelegt von d-uo |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2022 | ||
| 500 | |a Date Revised 10.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a INTRODUCTION: Patients with prostate cancer often present with reduced bone mineral density. We herein present real-world data (RWD) regarding osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) receiving androgen deprivation therapy (ADT) treated by German urologists in private practice | ||
| 520 | |a MATERIAL AND METHODS: This is a questionnaire-based study including members of d-uo ("Deutsche Uro-Onkologen", German uro-oncologists). Patients with nmHSPC between July 2019 and June 2020 were included. They were asked about start, type and duration of osteoprotection as well as supplementation with calcium and vitamin D | ||
| 520 | |a RESULTS: Between July 2019 and June 2020, a total of 3,692 patients with prostate cancer were seen at least once in one of the private practices of 15 urologists (all d-uo members). There were 844 patients (22.9%) with nmHSPC treated with ADT. Osteoprotection using denosumab or a bisphosphonate to prevent skeletal-related events (SRE) was applied in 183/844 patients (21.7%) with nmHSPC. In patients receiving osteoprotection, denosumab was chosen in 73.2% of patients and a bisphosphonate was chosen in 26.8% of patients. Supplementation with calcium and vitamin D was given in 84.7% of patients | ||
| 520 | |a CONCLUSION: Patients with nmHSPC received osteoprotection in 1/5 of patients. Of these, 3/4 received denosumab and 1/4 received a bisphosphonate. The majority of patients were additionally treated with calcium and vitamin D. In our study, osteoprotection in patients with nmHSPC was rather an exception | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Androgens |2 NLM | |
| 650 | 7 | |a Denosumab |2 NLM | |
| 650 | 7 | |a 4EQZ6YO2HI |2 NLM | |
| 650 | 7 | |a Calcium |2 NLM | |
| 650 | 7 | |a SY7Q814VUP |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 650 | 7 | |a Diphosphonates |2 NLM | |
| 700 | 1 | |a König, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Schönfelder, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Eichenauer, Rolf |e verfasserin |4 aut | |
| 700 | 1 | |a Johannsen, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Beuke, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Brenneis, Horst |e verfasserin |4 aut | |
| 700 | 1 | |a Burkert-Scholz, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Fieseler, Claus |e verfasserin |4 aut | |
| 700 | 1 | |a Jaeger, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Nitz, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Reese, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnolo, Allesandro |e verfasserin |4 aut | |
| 700 | 1 | |a Schröder, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Hempel, Elke |e verfasserin |4 aut | |
| 700 | 1 | |a Doehn, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Aktuelle Urologie |d 1981 |g 53(2022), 6 vom: 24. Dez., Seite 517-525 |w (DE-627)NLM121152979 |x 1438-8820 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:6 |g day:24 |g month:12 |g pages:517-525 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1954-6826 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 6 |b 24 |c 12 |h 517-525 | ||